

#10/2
2000
11-15-01
RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Patent Application of:
Erwin SI et al.

Appl. No.: 09/523,102

Filed: March 10, 2000

For: Methods and Compositions for
Treating and Preventing Retinal
Neovascularization

Art Unit: 1651

Examiner: B. Ozga

Atty. Docket: 13587.286

NOV 13 2001
TECH CENTER 1600/2900

Response Under 35 U.S.C. 111(a) to the Office Action Dated October 25, 2001

Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Office Action dated October 25, 2001, (Paper No. 9), Applicants submit the following amendments and remarks.

IN THE SPECIFICATION

Please insert the following paragraph into the specification at page 1 line 3 following the title:

-- ~~This application is a continuation-in-part of U.S. patent application 09/127,920, filed August 3, 1998.~~

Remarks

This application has been amended to recite a priority claim under 35 U.S.C. 120 to U.S. application number 09/127,920. No new matter is added by this amendment. Following the entry of this amendment, claims 1 – 66 will be pending in the instant application. Claims 1- 42 are being examined on their merits, and claims 43-66 stand withdrawn from consideration pursuant to a restriction requirement under 35 U.S.C. 121.